Pulmonary Function Testing for Neonatal Respiratory Disorders
(PUFFOR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand lung function in newborns, both preterm and term, with and without lung problems. Researchers use a gentle, non-invasive method called non-invasive forced airway oscillometry to measure lung function. The study includes infants who are at least 22 weeks gestational age and have been breathing without a ventilator for at least 12 hours. By comparing lung function across different groups, researchers hope to gain insights into conditions like respiratory distress syndrome and other common newborn lung issues. Parents or legal guardians must consent for their infants to participate. As an unphased trial, this study offers a unique opportunity to contribute to important research that could improve care for newborns with lung issues.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that non-invasive forced airway oscillometry is safe for neonatal pulmonary function testing?
Research has shown that non-invasive forced airway oscillometry safely checks lung function in newborns. This method uses gentle airwaves to assess a baby's lung performance. Being non-invasive, it avoids needles or surgery, ensuring comfort for infants.
No reports of harmful side effects have emerged from this technique. It has been successfully applied to both healthy newborns and those with breathing issues, offering valuable information without causing harm. This indicates that non-invasive forced airway oscillometry is well-tolerated and poses minimal risk to infants.12345Why are researchers excited about this trial?
Researchers are excited about using non-invasive forced airway oscillometry for neonatal respiratory disorders because it offers a safer and less invasive way to assess lung function in infants. Unlike traditional methods, which often involve more invasive techniques like intubation or sedation, this approach uses gentle oscillations of air to measure lung function without causing discomfort or harm to the baby. This method allows for both cross-sectional and longitudinal analysis, which can provide a more comprehensive understanding of how lung function develops or deteriorates over time in various neonatal conditions. Ultimately, this technique could lead to better diagnosis and monitoring of respiratory disorders in newborns, potentially improving outcomes for these vulnerable patients.
What evidence suggests that non-invasive forced airway oscillometry is effective for measuring pulmonary function in neonatal respiratory disorders?
Research has shown that non-invasive forced airway oscillometry, studied in this trial, effectively checks lung function in newborns. This technique distinguishes between healthy babies and those with conditions like transient tachypnea of the newborn (TTN) on their first day. Being non-invasive, it avoids needles or surgery, making it ideal for infants. Studies have found that this method provides important information about lung health and can monitor changes over time. This makes it a promising tool for understanding and managing breathing problems in newborns.12567
Who Is on the Research Team?
Namasivayam Ambalavanan, MD
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This trial is for infants born at or after 22 weeks of gestation who are off ventilators for at least 12 hours. It's open to those whose parents or guardians consent, but not to babies with terminal illnesses, neuromuscular conditions affecting breathing, major malformations, or if there's a decision to limit support.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Observation
Lung function is measured using non-invasive forced oscillometry in term and preterm infants with and without lung disease.
Follow-up
Participants are monitored for changes in lung function and response to therapeutic interventions.
What Are the Treatments Tested in This Trial?
Interventions
- Non-invasive forced airway oscillometry
Non-invasive forced airway oscillometry is already approved in European Union, United States, Canada for the following indications:
- Assessment of lung function in infants and adults
- Diagnosis of respiratory diseases such as asthma and COPD
- Assessment of lung function in infants and adults
- Monitoring of respiratory mechanics during mechanical ventilation and sleep
- Assessment of lung function in preterm infants
- Diagnosis of respiratory diseases such as bronchopulmonary dysplasia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor